Great news!
U.S. FDA Grants VistaGen Therapeutics Fast Track Designation For PH94B For Treatment Of Social Anxiety Disorder >VTGN
BY Dow Jones & Company, Inc.
— 8:30 AM ET 12/10/2019
U.S. FDA Grants VistaGen Therapeutics Fast Track Designation for PH94B for Treatment of Social Anxiety Disorder
VistaGen's PH94B is the first drug candidate to be granted U.S. FDA Fast Track designation for treatment of social anxiety disorder
PR Newswire
SOUTH SAN FRANCISCO, Calif., Dec. 10, 2019
SOUTH SAN FRANCISCO, Calif., Dec. 10, 2019 /PRNewswire/ -- VistaGen Therapeutics, Inc. ( VTGN ) , a clinical- stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet need, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for development of the Company's PH94B neuroactive nasal spray for on-demand treatment of social anxiety disorder (SAD).
The FDA's Fast Track process is designed to facilitate the development and review of new treatments for serious conditions with unmet medical need, such as SAD, with the purpose of getting innovative new treatment options to patients sooner. After successful Phase 2 development, VistaGen is preparing PH94B for Phase 3 development. PH94B has potential to be the first fast-acting, non-sedating, as-needed treatment for as many as 20 million individuals in the U.S. suffering from SAD.
"The FDA's grant of Fast Track designation for development of PH94B for SAD, which to our knowledge is the FDA's first Fast Track designation for a SAD drug candidate, is another important regulatory milestone for VistaGen and a key step forward in our development program for PH94B as a new generation anxiolytic. With a high global prevalence of anxiety disorders, including SAD, and alarming increases in dependency, addiction and even deaths associated with misuse of benzodiazepines, the urgency for a new non-addictive, non-sedating, fast-acting, as-needed treatment for SAD and other anxiety disorders is more important now than ever before. Based on clinical studies to date, PH94B, at non-systemic microgram doses, has strong potential to fill the large current treatment gap," said Shawn Singh, Chief Executive Officer of VistaGen.
